These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 994932)

  • 81. Occlusive digital artery disease in patients with Raynaud's phenomenon.
    Zweifler AJ; Trinkaus P
    Am J Med; 1984 Dec; 77(6):995-1001. PubMed ID: 6334442
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Appearance of a gastric ulcer during diphosphonate therapy in a woman with CRST syndrome.
    Saunders RL
    South Med J; 1977 Nov; 70(11):1327-9. PubMed ID: 411174
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Raynaud, digital ulcers and calcinosis in scleroderma.
    Nitsche A
    Reumatol Clin; 2012; 8(5):270-7. PubMed ID: 22835924
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Calcinosis in dermatomyositis treated with probenecid.
    Skuterud E; Sydnes OA; Haavik TK
    Scand J Rheumatol; 1981; 10(2):92-4. PubMed ID: 7017918
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Reproducibility of cold provocation in patients with Raynaud's phenomenon.
    Wigley FM; Malamet R; Wise RA
    J Rheumatol; 1987 Aug; 14(4):751-5. PubMed ID: 3668980
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Thromboangiitis obliterans: a rare cause of a reversible Raynaud's phenomenon.
    Noël B; Krayenbühl B; Cerottini JP; Guggisberg D; Buxtorf K; Pires A; Panizzon RG
    Dermatology; 2000; 200(4):363-5. PubMed ID: 10894979
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Prolonged improvement of Raynaud's phenomenon and scleroderma after recombinant tissue plasminogen activator therapy.
    Fritzler MJ; Hart DA
    Arthritis Rheum; 1990 Feb; 33(2):274-6. PubMed ID: 2106327
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
    Fries R; Shariat K; von Wilmowsky H; Böhm M
    Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Raynaud's phenomenon in rheumatoid arthritis.
    Grassi W; Blasetti P; Core P; Cervini C
    Br J Rheumatol; 1994 Feb; 33(2):139-41. PubMed ID: 8162478
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Severe Raynaud's phenomenon with yohimbine therapy for erectile dysfunction.
    Johnson S; Iazzetta J; Dewar C
    J Rheumatol; 2003 Nov; 30(11):2503-5. PubMed ID: 14677199
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Efficacy of bosentan in the treatment of Raynaud's phenomenon in patients with systemic sclerosis never treated with prostanoids.
    Parisi S; Bruzzone M; Centanaro Di Vittorio C; Laganà A; Peroni CL; Fusaro E
    Reumatismo; 2014 Mar; 65(6):286-91. PubMed ID: 24705032
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Association between Raynaud's phenomenon and migraine in a random population of hospital employees.
    O'Keeffe ST; Tsapatsaris NP; Beetham WP
    J Rheumatol; 1993 Jul; 20(7):1187-8. PubMed ID: 8371215
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Inhaled iloprost for the treatment of Raynaud's phenomenon.
    Pakozdi A; Howell K; Wilson H; Fox S; Gonzalez L; Black CM; Denton CP
    Clin Exp Rheumatol; 2008; 26(4):709. PubMed ID: 18799113
    [No Abstract]   [Full Text] [Related]  

  • 94. Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon.
    Teh LS; Manning J; Moore T; Tully MP; O'Reilly D; Jayson MI
    Br J Rheumatol; 1995 Jul; 34(7):636-41. PubMed ID: 7670782
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Topical glyceryl trinitrate as adjunctive treatment in Raynaud's disease.
    Franks AG
    Lancet; 1982 Jan; 1(8263):76-7. PubMed ID: 6119495
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Clinical correlation analysis of 137 patients with Raynaud's phenomenon.
    Velayos EE; Robinson H; Porciuncula FU; Masi AT
    Am J Med Sci; 1971 Dec; 262(6):347-56. PubMed ID: 5146924
    [No Abstract]   [Full Text] [Related]  

  • 97. Harnessing the therapeutic potential therapeutic efficacy of α-1 adrenergic blockers for Raynaud's phenomenon and digital ischaemia secondary to central nervous system stimulants used for attention deficit hyperactivity disorder.
    Hughes M; Umair HM; Sandler RD; Alunno A; Matucci-Cerinic M
    Semin Arthritis Rheum; 2022 Dec; 57():152114. PubMed ID: 36356481
    [No Abstract]   [Full Text] [Related]  

  • 98. Raynaud's phenomenon?
    Appleby BR
    Med J Aust; 1978 Oct; 2(9):437, 439. PubMed ID: 732742
    [No Abstract]   [Full Text] [Related]  

  • 99. Serotonin reuptake inhibitors, Raynaud's phenomenon and erythromelalgia.
    Rey J; Cretel E; Jean R; Pastor MJ; Durand JM
    Rheumatology (Oxford); 2003 Apr; 42(4):601-2. PubMed ID: 12649412
    [No Abstract]   [Full Text] [Related]  

  • 100. A Case of Calcinosis Circumscripta.
    Woolf DL
    Ann Rheum Dis; 1947; 6(4):208-18. PubMed ID: 18623770
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.